KORU Medical Q2 FY26 net income turns to profit at $252,449; revenue rises 18% to $12 million
KRMD•Q2 results
- KORU Medical Systems posted Q2 net revenues up 18.2% to $12 million, driven by 12.4% domestic core growth to $8 million.
- International core net revenues climbed 59.1% to $3.47 million, supported by distributor purchases tied to pre-filled syringe conversions.
- GAAP net income swung to $252,449, versus a prior-year loss; GAAP gross margin widened 1.6 percentage points to 65.1%.
Business updates and outlook
- Acquired a connected monitoring technology asset; withdrew its U.S. 510(k) application for FreedomEDGE with Phesgo and shifted oncology focus to higher-volume molecules.
- Updated 2026 guidance: net revenues of $47.5 million-$48.5 million, gross margin of 62%-64%, positive adjusted EBITDA, year-end cash above $7.5 million.
